-
Exclusive: Egalet CEO Talks Drug Approvals, 21st Century Cures Act And Winning The War On Opioid Abuse
Thursday, January 19, 2017 - 9:37am | 1104Egalet Corp (NASDAQ: EGLT) was surely one of the most watched biotechs of the fourth quarter of 2016. After the company announced the Food and Drug Administration would miss its PDUFA decision date for Egalet’s opioid-based pain medication ARYMO ER, investors waited impatiently for news of a...